These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
760 related articles for article (PubMed ID: 27366006)
1. Early Changes in the Serotype Distribution of Invasive Pneumococcal Isolates from Children after the Introduction of Extended-valent Pneumococcal Conjugate Vaccines in Korea, 2011-2013. Cho EY; Choi EH; Kang JH; Kim KH; Kim DS; Kim YJ; Ahn YM; Eun BW; Oh SH; Cha SH; Cho HK; Hong YJ; Kim KN; Kim NH; Kim YK; Kim JH; Lee H; Lee T; Kim HM; Lee KS; Kim CS; Park SE; Kim YM; Oh CE; Ma SH; Jo DS; Choi YY; Lee J; Bae GR; Park O; Park YJ; Kim ES; Lee HJ J Korean Med Sci; 2016 Jul; 31(7):1082-8. PubMed ID: 27366006 [TBL] [Abstract][Full Text] [Related]
2. Antibiotic resistance and serotype distribution of invasive pneumococcal diseases before and after introduction of pneumococcal conjugate vaccine in the Kingdom of Saudi Arabia (KSA). Shibl AM; Memish ZA; Al-Kattan KM Vaccine; 2012 Dec; 30 Suppl 6():G32-6. PubMed ID: 23228355 [TBL] [Abstract][Full Text] [Related]
3. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait. Mokaddas E; Albert MJ Vaccine; 2012 Dec; 30 Suppl 6():G37-40. PubMed ID: 23228356 [TBL] [Abstract][Full Text] [Related]
4. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Isaacman DJ; McIntosh ED; Reinert RR Int J Infect Dis; 2010 Mar; 14(3):e197-209. PubMed ID: 19700359 [TBL] [Abstract][Full Text] [Related]
5. Pneumococcal serotype evolution in Western Europe. Tin Tin Htar M; Christopoulou D; Schmitt HJ BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008 [TBL] [Abstract][Full Text] [Related]
6. Serotype distribution and antibiotic resistance of Streptococcus pneumoniae isolated from invasive infections after optional use of the 7-valent conjugate vaccine in Korea, 2006-2010. Cho EY; Lee H; Choi EH; Kim YJ; Eun BW; Cho YK; Kim YK; Jo DS; Lee HS; Lee J; Kim MN; Kim DS; Lee HJ Diagn Microbiol Infect Dis; 2014 Apr; 78(4):481-6. PubMed ID: 24529940 [TBL] [Abstract][Full Text] [Related]
7. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490 [TBL] [Abstract][Full Text] [Related]
8. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines. Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924 [TBL] [Abstract][Full Text] [Related]
9. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine. Sharma D; Baughman W; Holst A; Thomas S; Jackson D; da Gloria Carvalho M; Beall B; Satola S; Jerris R; Jain S; Farley MM; Nuorti JP Pediatr Infect Dis J; 2013 Feb; 32(2):e45-53. PubMed ID: 23080290 [TBL] [Abstract][Full Text] [Related]
10. Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012-2014. Nakano S; Fujisawa T; Ito Y; Chang B; Suga S; Noguchi T; Yamamoto M; Matsumura Y; Nagao M; Takakura S; Ohnishi M; Ihara T; Ichiyama S Vaccine; 2016 Jan; 34(1):67-76. PubMed ID: 26602268 [TBL] [Abstract][Full Text] [Related]
11. Decreasing incidence and changes in serotype distribution of invasive pneumococcal disease in persons aged under 18 years since introduction of 10-valent and 13-valent conjugate vaccines in Portugal, July 2008 to June 2012. Aguiar SI; Brito MJ; Horacio AN; Lopes JP; Ramirez M; Melo-Cristino J; ; Euro Surveill; 2014 Mar; 19(12):20750. PubMed ID: 24698140 [TBL] [Abstract][Full Text] [Related]
12. Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children. Ryman J; Sachs JR; Yee KL; Banniettis N; Weaver J; Weiss T Expert Rev Vaccines; 2024; 23(1):60-68. PubMed ID: 38073483 [TBL] [Abstract][Full Text] [Related]
13. Pneumococcal Mastoiditis in Children Before and After the Introduction of Conjugate Pneumococcal Vaccines. Koutouzis EI; Michos A; Koutouzi FI; Chatzichristou P; Parpounas K; Georgaki A; Theodoridou M; Tsakris A; Syriopoulou VP Pediatr Infect Dis J; 2016 Mar; 35(3):292-6. PubMed ID: 26569193 [TBL] [Abstract][Full Text] [Related]
14. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec. De Wals P; Lefebvre B; Deceuninck G; Longtin J Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962 [TBL] [Abstract][Full Text] [Related]
15. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). Nuorti JP; Whitney CG; MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868 [TBL] [Abstract][Full Text] [Related]
16. Non-susceptibility trends and serotype coverage by conjugate pneumococcal vaccines in a Tunisian paediatric population: a 10-year study. Charfi F; Smaoui H; Kechrid A Vaccine; 2012 Dec; 30 Suppl 6():G18-24. PubMed ID: 23228353 [TBL] [Abstract][Full Text] [Related]
17. Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany. van der Linden M; Falkenhorst G; Perniciaro S; Imöhl M PLoS One; 2015; 10(7):e0131494. PubMed ID: 26132078 [TBL] [Abstract][Full Text] [Related]
18. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden. Galanis I; Lindstrand A; Darenberg J; Browall S; Nannapaneni P; Sjöström K; Morfeldt E; Naucler P; Blennow M; Örtqvist Å; Henriques-Normark B Eur Respir J; 2016 Apr; 47(4):1208-18. PubMed ID: 26797033 [TBL] [Abstract][Full Text] [Related]
19. Changes in the Serotype Distribution among Antibiotic Resistant Carriage Streptococcus pneumoniae Isolates in Children after the Introduction of the Extended-Valency Pneumococcal Conjugate Vaccine. Lee JK; Yun KW; Choi EH; Kim SJ; Lee SY; Lee HJ J Korean Med Sci; 2017 Sep; 32(9):1431-1439. PubMed ID: 28776337 [TBL] [Abstract][Full Text] [Related]
20. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020. Link-Gelles R; Taylor T; Moore MR; Vaccine; 2013 May; 31(22):2572-7. PubMed ID: 23583813 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]